Novo Nordisk A/S saw its stock rise by approximately 7% in early market trading after receiving FDA approval for its Wegovy weight-loss pill, the first oral GLP-1 treatment for weight management. Expected to launch in the U.S. in January 2026, this development signals a significant moment for the GLP-1 market, where Novo Nordisk already commands a 59% global share. Despite this surge, shares remain over 50% below previous highs, highlighting the dynamic nature of the company's market position.
“Novo Nordisk A/S (NYSE:NVO) · shares are up · early market trading · about 7%”
“Novo Nordisk A/S (NYSE:NVO) · said · received approval · U.S. Food and Drug Administration for Wegovy pill as an oral GLP-1 treatment”
“Novo Nordisk A/S (NYSE:NVO) · expects to launch · the product in the U.S. · in early January 2026”
“Novo Nordisk A/S · shares are up · about 7% in early market trading · true”
“Novo Nordisk A/S · received · U.S. Food and Drug Administration approval for its Wegovy pill · true”
“Novo Nordisk A/S · expects to launch · the product in the U.S. in early January 2026 · true”
“Novo Nordisk A/S shares · jumped · premarket trade · 9%”
“Novo Nordisk · got · official US approval · Wegovy weight-loss pill”
“Novo Nordisk · won US approval for · weight-loss pill · oral Wegovy”
“Novo Nordisk · plans to offer the weight-loss pill · to cash-paying buyers · from day one”
“Novo Nordisk · won · US approval · for weight-loss pill”
“Shares of Novo Nordisk · jumped · before the bell · Tuesday”
